First clinical proof-of-concept that FMT can overcome resistance to ICIs
Crossref DOI link: https://doi.org/10.1038/s41571-021-00502-3
Published Online: 2021-03-19
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Elkrief, Arielle
Routy, Bertrand
Text and Data Mining valid from 2021-03-19
Version of Record valid from 2021-03-19
Article History
First Online: 19 March 2021
Competing interests
: B.R. declared consulting and advisory roles for Davoltera, EverImmune, Kaleido and Vedanta. A.E. declares no competing interests.